Plain-English translation of NCT06644781 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new cancer medication called (I-DXd) to see if it helps people with advanced esophageal squamous cell carcinoma live longer and control their cancer better than standard chemotherapy. The medication is given as an intravenous infusion (through your vein) every three weeks. Researchers want to compare how well this treatment works compared to other chemotherapy options.
Esophageal squamous cell carcinoma is a serious cancer, and people whose cancer continues to grow after initial chemotherapy and immunotherapy treatment need better options. This medication targets a specific protein on cancer cells, and early research suggests it may help control this type of cancer more effectively than current standard treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication or one of the standard chemotherapy options. If you receive the new treatment, you'll get an intravenous infusion of the medication on day 1 of each 21-day cycle. You'll have regular clinic visits for infusions, blood tests, and imaging scans to monitor how well the treatment is working and to check for any side effects. The trial will track your overall survival and how your cancer responds to treatment over time.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States